scholarly journals Differential expression of maternal embryonic leucine zipper kinase in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Leucine Zipper ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding maternal embryonic leucine zipper kinase, MELK, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). MELK was also differentially expressed in bulk tumor in human breast cancer (3). MELK mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of MELK in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of MELK was correlated with distant metastasis-free survival in patients with basal-like 1 and luminal androgen receptor subtype disease. MELK may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of RecQ-like helicase 4 in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding RecQ-like helicase 4, RECQL4, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). RECQL4 was also differentially expressed in bulk tumor in human breast cancer (3). RECQL4 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of RECQL4 in primary tumors of the breast was correlated with recurrence-free survival in patients with HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of RECQL4 was correlated with distant metastasis-free survival in patients with basal-like 2 subtype disease. RECQL4 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of histone cluster 3, H2a in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer are predicted to benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 3, H2a, HIST3H2A, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST3H2A was also differentially expressed in bulk tumor in human breast cancer (3). HIST3H2A mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST3H2A in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A and HER2+ type cancer, while within triple negative breast cancer, primary tumor expression of HIST3H2A was correlated with distant metastasis-free survival in patients with immunomodulatory, mesenchymal, and luminal androgen receptor subtype disease. HIST3H2A may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of histone cluster 1, H2bd in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bd, HIST1H2BD, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BD was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BD mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BD in primary tumors of the breast was correlated with recurrence-free survival in patients with luminal A, HER2+ and normal-like subtype cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BD was correlated with distant metastasis-free survival in patients with basal-like 1 subtype disease. HIST1H2BD may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of histone cluster 1, H2am in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Recurrence Free Survival ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2am, HIST1H2AM, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2AM was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2AM mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2AM in primary tumors of the breast was correlated with recurrence-free survival in patients with normal-like type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2AM was correlated with recurrence-free survival in patients with basal-like 1 subtype disease. HIST1H2AM may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of histone cluster 1, H2bf in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bf, HIST1H2BF, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BF was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BF mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BF in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BF was correlated with distant metastasis-free survival in patients with mesenchymal stem-like subtype disease. HIST1H2BF may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of histone cluster 1, H2bb in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Recurrence Free Survival ◽  
Primary Tumors ◽  
Free Survival ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bb, HIST1H2BB, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BB was also differentially expressed in bulk tumor in human breast cancer (3). HIST1H2BB mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BB in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like and luminal B type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BB was correlated with recurrence-free survival in patients with basal-like 1, basal-like 2 and mesenchymal stem-like subtype disease. HIST1H2BB may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of cyclin A2 in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Ductal Cells ◽  
Cyclin A2

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cyclin A2, CCNA2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CCNA2 was also differentially expressed in bulk tumor in human breast cancer (3). CCNA2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CCNA2 in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of CCNA2 was correlated with overall survival in patients with basal-like 1, basal-like 2, and mesenchymal subtype disease. CCNA2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of abnormal spindle microtubule assembly in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Microtubule Assembly ◽  
Spindle Microtubule ◽  
Primary Tumors ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding abnormal spindle microtubule assembly, ASPM, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). ASPM was also differentially expressed in bulk tumor in human breast cancer (3). ASPM mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of ASPM in primary tumors of the breast was correlated with recurrence-free survival in patients with basal-like and luminal A type cancer, while within triple negative breast cancer, primary tumor expression of ASPM was correlated with overall survival in patients with basal-like 1 subtype disease. ASPM may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of histone cluster 1, H2bh in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Survival Data ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Significant Differential Expression ◽  
Primary Tumors ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding histone cluster 1, H2bh, HIST1H2BH, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). HIST1H2BH was also differentially expressed in the brain metastases of patients with metastastic breast cancer (3). HIST1H2BH mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of HIST1H2BH in primary tumors of the breast was correlated with overall survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of HIST1H2BH was correlated with distant metastasis-free survival in patients with immunomodulatory subtype disease. HIST1H2BH may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

scholarly journals Differential expression of cell division cycle-associated 5 in triple negative breast cancer.

2021 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cell Division ◽  
Differential Expression ◽  
Tumor Cells ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Differentially Expressed ◽  
Primary Tumors ◽  
Ductal Cells

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cell division cycle-associated 5, CDCA5, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CDCA5 was also differentially expressed in bulk tumor in human breast cancer (3). CDCA5 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CDCA5 in primary tumors of the breast was correlated with overall survival in patients with luminal A type cancer, while within triple negative breast cancer, primary tumor expression of CDCA5 was correlated with overall survival in patients with mesenchymal subtype disease. CDCA5 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Sign in / Sign up

Export Citation Format

Share Document